Executive summary
US 6,517,847 is directed to topical, lotion-type semisolid compositions and related preparation/packaging methods that use a lightly cross-linked hydrophilic polyacrylic acid polymer (matrix former) to deliver a pH-controlled, low-viscosity ( <15,000 cP) regimen for treatment of skin disorders. The claims are broad on therapeutic class (antibiotic/imidazole/retinoid/corticosteroid/NSAID) and specify key formulation guardrails: pH ~3 to ~9, low viscosity, up to ~25% water-miscible solvent, optional preservative, water, and an oil phase + surfactant to form a lotion/emulsion. Dependent claims narrow to specific active pairings (notably clindamycin phosphate + tretinoin and antibiotic+corticosteroid combinations) and add specific lotion pH and concentration windows.
Below is a claim-scope and landscape map, framed around infringement-relevant elements (polymer identity/functional role, lotion structure, pH/viscosity ceilings, actives and concentration bands, and method-of-use/prep/packaging elements), plus the likely competitive design-around surface (pH, viscosity, polymer type/crosslink density, lotion/emulsion requirement, and active selection).
US Patent 6,517,847 scope: what exactly is claimed for topical low-viscosity pH-controlled polyacrylic acid lotion?
What is the core formulation claim scope in claim 1?
Independent claim 1 claims a composition with the following required structure and parameters:
-
Target use / intended therapy
- “for treating a skin disorder in a human subject.”
(This is an intended-use limitation; practically, it aligns the drug/labeling use to dermatologic disorders.)
-
Critical physicochemical constraints
- pH: “about 3 to about 9”
- Viscosity: “less than about 15,000 cP”
-
“Consists essentially of” composition frame
The claim uses “consists essentially of,” which permits inclusion of additional components that do not materially affect the basic and novel characteristics.
-
Mandatory composition components (a)–(g)
- (a) therapeutically effective amount of at least one compound useful for treating such disorder
- (b) pharmaceutically-acceptable, lightly cross-linked hydrophilic polyacrylic acid polymer compatible with the compound
- (c) pharmaceutically acceptable base to adjust pH
- (d) up to about 25% w/w water miscible solvent
- (e) optional preservative
- (f) water
- (g) at least one surfactant in combination with an oil phase sufficient to form a lotion
Key infringement hook: the formulation must be a lotion/emulsion system made by surfactant + oil phase.
Claim 1 practical “lock points” for infringement
A product will most plausibly read on claim 1 if it includes:
- A lotion/emulsion with oil phase + surfactant
- A hydrophilic polyacrylic acid polymer that is lightly cross-linked
- A formulation with pH between ~3 and ~9
- Viscosity <15,000 cP
- A water-miscible solvent load ≤25% w/w
- Therapeutic actives that fit within the claimed “compound useful for treating such disorder”
What actives are covered under dependent claims (claim 2–6, 8–9)?
Claim 2 expands specificity by defining representative active classes:
- antibiotic, imidazole, retinoid, corticosteroid, or NSAID.
Claim 3–4:
- antibiotic alone or antibiotic + corticosteroid or retinoid
- claim 4 is antibiotic alone (further narrowed by claim 5).
Claim 5 (antibiotic + corticosteroid pairings) requires:
- antibiotic is clindamycin phosphate
- corticosteroid is one of: desonide, hydrocortisone valerate, fluocinolone acetonide, hydrocortisone butyrate, triamcinolone acetonide
Claim 6 (antibiotic + retinoid pairing) requires:
- antibiotic is clindamycin phosphate
- retinoid is tretinoin
Claim 8–9 (sole corticosteroid active) narrows to:
- corticosteroid sole active is one of the listed set:
diflorasone diacetate, fluticasone propionate, halobetasol propionate, budesonide, desonide, betamethasone dipropionate, clobetasol propionate, hydrocortisone butyrate, betamethasone valerate, fluocinolone acetonide, triamcinolone acetonide.
What is the specific clindamycin phosphate + tretinoin lotion window (claim 7 and claim 19/27)?
Claim 7 turns claim 1 into a tight formulation band:
- pH: about 5 to 6
- Lotion composition “consists essentially of”:
- (a)
- (i) about 0.5% to 2.0% w/w clindamycin phosphate
- (ii) about 0.01% to 0.05% w/w tretinoin
- (b) polyacrylic acid polymer: about 0.1% to 0.5% w/w
- (c) base to adjust pH
- (d) water-miscible solvent
- (e) preservative <0.2%
- (f) water
- (g) oil phase + at least one surfactant sufficient to form an emulsion/lotion
Claim 19 mirrors the same clindamycin+tretinoin lotion band but contains a textual defect (“about 0. 1% to about 0.5% w/w%”) and repeats the essential elements.
Claim 27 is a method-style parallel but repeats the same clindamycin+tretinoin target windows (including a specific tretinoin range “0.010/% to 0.05%,” consistent with the intention of 0.01–0.05% though the text formatting is off).
What packaging and labeling limitations exist (claims 10–11)?
- Claim 10: composition of claim 1 with a container that accurately administers a portion for topical administration
- Claim 11: claim 10 plus labeling instructions for use in treating the skin disorder
These elements are typically easier to satisfy for consumer-facing topical products but are also comparatively easy to avoid via alternative packaging/labeling facts, though “labeling instructions” can still attach to product reality.
US Patent 6,517,847 method-of-use and preparation coverage: how broad are claims 12–31?
What does claim 12 cover (method for treating a skin disorder)?
Claim 12 is the method-of-use analogue of claim 1:
- Topically administer to affected skin
- A composition meeting:
- pH ~3 to ~9
- viscosity <15,000 cP
- “consists essentially of” components (a)–(g) exactly aligned to claim 1
- In an amount and for a period sufficient to improve the skin disorder.
What disorders and dosing frequency are specified in dependent claims?
- Claim 13: inflammatory skin disorder, acne, or rosacea
- Claim 14: administered once a day for the period sufficient to improve
- Claim 15: compound is antibiotic/imidazole/retinoid/corticosteroid/NSAID
- Claims 16–18: antibiotic combinations; includes clindamycin phosphate + tretinoin in claim 18
What is the tight clindamycin phosphate + tretinoin method window (claims 17–19)?
- Claim 18: clindamycin phosphate + tretinoin
- Claim 19: pH about 5 to 6 and the same concentration windows:
- 0.5% to 2.0% clindamycin phosphate
- 0.01% to 0.05% tretinoin
- polymer 0.1% to 0.5%
- preservative <0.2%
- lotion with oil phase + surfactant
What does claim 22 cover (method of preparing the composition)?
Claim 22 covers a manufacturing/preparation method for a lotion meeting the pH/viscosity constraints:
- Combine water and optionally water miscible solvent with:
- therapeutically effective amount of at least one compound
- lightly cross-linked hydrophilic polyacrylic acid polymer
- Adjust pH to ~3–9
- Optionally combine preservative, water miscible solvent (if not already), and surfactant + oil phase to form lotion
Dependent claims 23–31 narrow along the same active classes, clindamycin/tretinoin band, corticosteroid-only alternatives, and add container/labeling placement steps (claims 30–31).
What is the likely litigation posture for method claims?
From an enforcement perspective, the method claims can support:
- direct infringement by manufacturers if preparation is replicated
- inducement or contribution arguments if a generic/distributor provides a preparation recipe that maps to the steps and uses the claimed composition parameters
But as a practical matter, “method of preparing” claims are often less frequently asserted than product/formulation claims unless there is clear evidence about manufacturing instructions, controlled processes, or contract manufacturing disclosures.
How should US 6,517,847 be read as a “polyacrylic acid lotion” patent rather than a specific drug patent?
Which claim elements are likely “essential” vs “switchable” for design-around?
Most essential / hardest to avoid without changing the product’s core:
- The polymer limitation: “lightly cross-linked hydrophilic polyacrylic acid polymer”
- The lotion architecture: “oil phase in combination with at least one surfactant sufficient to form a lotion”
- The pH band (claim 1: ~3–9; clindamycin+tretinoin dependent: ~5–6)
- Viscosity ceiling (<15,000 cP)
- Solvent ceiling (≤25% w/w, claim 1; dependent claims do not restate the solvent cap but retain the “consists essentially of” frame)
More switchable depending on the marketed indication/product:
- Choice of therapeutic compound: dependent claims include specific drug pairs, but independent claim 1 is class-based
- Concentration windows: only dependent claim 7/19/27 tie to specific ranges for clindamycin phosphate and tretinoin
- Container accuracy and labeling instructions: claims 10–11, 30–31
Design-around surface for generics or follow-on products
Because claim 1 is broad, meaningful design-around usually requires changing at least one of the claim’s structural anchors:
-
Replace the polymer system
- Change from lightly cross-linked polyacrylic acid to a different polymer chemistry, or remove/alter cross-linking behavior such that it is not “lightly cross-linked” polyacrylic acid.
This is the highest-leverage lever.
-
Break the lotion/emulsion requirement
- Use a different topical base type (gel, cream without the “oil phase + surfactant lotion sufficient” structure, or a non-emulsion system).
Claim language ties to lotion formation.
-
Move outside pH/viscosity windows
- Adjust pH outside ~3–9 or viscosity to ≥15,000 cP (though that can be difficult without changing feel/performance).
For the clindamycin+tretinoin band, moving pH outside ~5–6 or shifting concentrations out of the stated windows is a direct path.
-
Alter solvent load
- For claim 1, pushing water-miscible solvent beyond ~25% w/w could break the “up to” requirement, but may be incompatible with product stability or patient acceptability.
What patents likely matter around US 6,517,847: how to map the landscape by claim theme?
Landscape buckets that typically co-exist with this kind of formulation patent
Even without relying on a single catalog record, patents in this formulation class usually cluster into these buckets, each of which can create cumulative blocking positions for a topical generic or reformulation:
-
Polymer system patents
- Polyacrylic acid gels/lotion matrices
- Cross-linking methods and “lightly cross-linked” definitions
- Rheology control to achieve target viscosity bands
These are often earlier than the drug-actives patents and can create platform barriers.
-
Drug combination compatibility patents
- Antibiotic + retinoid co-formulation stability
- Antibiotic salt form compatibility (e.g., clindamycin phosphate)
- Retinoid stability under pH and solvent systems (e.g., tretinoin)
- Preservative systems that work with both actives
These map to claims 5–7 and 18–19.
-
Acne/rosacea method-of-use patents
- Once-daily dosing protocols
- Skin-condition-specific claims
These map to claims 13–14 and 12.
-
Device and packaging/labeling patents
- Accurate-dose containers for topical administration
- Labeling and instructions as limitations
These map to claims 10–11 and 30–31.
-
Alternative topical base composition patents
- Same actives but different vehicles (gels, foams, creams, microemulsions)
These are the most common design-around approaches if polymer/rheology changes are required.
How strong is the patent estate likely to be, based on claim architecture?
The claim set is structured to cover:
- a broad vehicle platform (claim 1/12/22)
- multiple dependent active-class permutations (claims 2, 8–9)
- specific high-value active combinations (clindamycin phosphate with tretinoin; clindamycin with several corticosteroids)
- narrow formulation windows for clindamycin+tretinoin (claims 7, 19, 27)
- treatment and once-daily use (claims 12–14)
- packaging and labeling tied to dose delivery (claims 10–11, 30–31)
That pattern typically produces a “thicket” effect, where a competitor has to clear both vehicle and active-pair constraints, not just an individual concentration range.
Key infringement analysis: where are the high-risk claim targets for a topical product?
If a product is a clindamycin phosphate + tretinoin lotion, what parts of the claims are most likely to drive exposure?
For a clindamycin+tretinoin lotion, the highest-risk elements are:
- the vehicle polymer being a lightly cross-linked hydrophilic polyacrylic acid polymer
- the pH (claim 7/19/27: ~5–6; claim 1/12: ~3–9)
- viscosity <15,000 cP
- concentration band:
- 0.5%–2.0% w/w clindamycin phosphate
- 0.01%–0.05% w/w tretinoin
- presence of oil phase + surfactant sufficient to form a lotion
- optional preservative <0.2% (dependent claim 7/19/27)
If a product is clindamycin phosphate + corticosteroid, which claims are most relevant?
- claim 5 for formulation: clindamycin phosphate + one of the listed corticosteroids
- claim 16–17 for method constructs pairing
- claim 20–21 if corticosteroid is sole active (not the clindamycin pair)
If a product is a corticosteroid-only lotion, what is the exposure route?
- claim 8–9 for formulation using specific corticosteroids
- claim 20–21 for method of treatment
Key takeaways
- US 6,517,847 claims a topical lotion/emulsion platform defined by pH ~3–9, viscosity <15,000 cP, and a lightly cross-linked hydrophilic polyacrylic acid polymer plus oil/surfactant lotion architecture.
- Dependent claims create direct product-specific risk for clindamycin phosphate + tretinoin at pH ~5–6 with tight 0.5%–2.0% clindamycin phosphate and 0.01%–0.05% tretinoin windows and a polymer band of 0.1%–0.5%.
- The landscape is best evaluated by vehicle platform (polymer/rheology/lotion formation) and by high-value drug-pair combinations (clindamycin+tretinoin; clindamycin+corticosteroid). Clearing only one dimension usually does not clear the claim set.
FAQs
- How do “consists essentially of” limits affect allowable excipients under US 6,517,847?
- What is the most direct design-around if a generic wants to avoid clindamycin phosphate + tretinoin concentration-range infringement?
- Does US 6,517,847 require a specific viscosity measurement method or is it only a numerical ceiling?
- Are the container-dose and labeling-instructions limitations enforceable independent of formulation changes?
- Which claim strategy is more effective: changing the polymer system or changing pH/viscosity and maintaining the polymer?
References (APA)
- U.S. Patent No. 6,517,847.
